Part B: Genome Editing for Functional Genomics Screens Conference - Part 2 header

About This Conference:

Cambridge Healthtech Institute’s eleventh annual conference on Genome Editing for Functional Genomics Screens will bring together experts to try to figure out how and where genome editing can be best applied in functional screening. What are the different tools and reagents that can be used, and based on those choices what are the downstream challenges encountered with assay design and data analysis? What are the strengths and limitations of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) -based screens, when compared to siRNA and shRNA screens? Can some of the lessons learned from the early days of RNAi screening, help with setting up these newer screens? Screening experts will share their experiences leveraging the utility of gene editing for creating cell lines and models for a wide range of applications and screening platforms.

shRNA and CRISPR Screens: Competing or Complementing?

Creating a State-of-the-Art Pipeline for RNAi and Gene Editing in an Academic Setting

Ralph J. Garippa, Ph.D., Director, RNAi Core Facility, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center

Exploring the Secretory Pathway Using ER-Trafficking Toxins, High-Complexity shRNA Libraries, and Genetic Interaction Maps

Michael Bassik, Ph.D., Assistant Professor, Department of Genetics, Stanford University

Utilizing CRISPR/Cas9 for Functional Screening

Analyses of Signaling Networks in Drosophila

Norbert Perrimon Ph.D., Professor, Department of Genetics, Harvard Medical School and Investigator, Howard Hughes Medical Institute

Genome-Scale CRISPR Knock-out Screen in Human Cancer and Stem Cells

Neville Sanjana, Ph.D., Simons Postdoctoral Fellow, Laboratory of Dr. Feng Zhang, Broad Institute and the Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology

Utilizing 3D and Stem Cell Cultures for Functional Screening

Relevance of 3D Cell Culture Models and siRNA Screens for Target Identification and Drug Development

Geoffrey A. Bartholomeusz, Ph.D., Assistant Professor and Director, siRNA Core Facility, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center

Integrating Tools for Data Analytics and Visualization

Integrating High-Throughput Imaging and Genomics to Identify Drug Combinations in Cancer

Arvind Rao, Ph.D., Assistant Professor, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center

CARD: A Platform for Comprehensive and Integrative Analysis of RNAi Screen Data

Bhaskar Dutta, Ph.D., Staff Scientist, Laboratory of Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health

TECHNOLOGY PANEL: Tools for Next-Generation Functional Genomics Screens

Moderator: Christophe Echeverri, Ph.D., CEO & CSO, Cenix BioScience USA, Inc.

This panel will bring together 4-5 technical experts from leading technology and service companies to discuss screening trends and improvements in assay platforms and reagents that users can expect to see in the near future.

(Opportunities Available for Sponsoring Panelists)

Topics to be covered:

-For what types of applications will emerging CRISPR-Cas9 capabilities replace RNAi, as opposed to complementing it?

-What efforts are being made to update RNAi reagents to help users tackle off-target effects?

-To what degree are vendors making efforts to address the risk of off-target effects with CRISPR-Cas9 reagents?

-Are there plans to build and offer genome-scale CRISPR-Cas9 libraries only for pooled, selection-based screening or also for arrayed screening?





green arrow VIEW ALL SPONSORS 



The exhibit hall was sold out in 2013, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2014, contact:

Jon Stroup
Business Development Manager